Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Conantokin-t** is a 21-amino acid peptide isolated from the venom of the fish-hunting cone snail, *Conus tulipa*. It is part of the conantokin family, characterized by a high content of gamma-carboxyglutamate (Gla) residues. Conantokin-t acts as a potent antagonist of the N-methyl-D-aspartate receptor (NMDAR), inhibiting receptor-mediated calcium influx in central nervous system (CNS) neurons. Mechanistically, it nonselectively antagonizes multiple NMDAR subunits (notably both NR2A/GRIN2A and NR2B/GRIN2B), modulating excitatory synaptic transmission via interaction with glutamate and polyamine recognition sites on the receptor[1][2][3][5][9][10]. Its peptide structure adopts an alpha-helical conformation even in aqueous solutions[6][7]. Conantokin-t, along with other conantokins, has been explored at the preclinical and early clinical stages for potential use as a neuroprotective and analgesic agent, but no approved clinical applications exist and development has been discontinued for human use due to multiple challenges in clinical translation[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conantokin-t.